Literature DB >> 2304490

Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. A large-scale French experience.

L Silvestre1, C Dubois, M Renault, Y Rezvani, E E Baulieu, A Ulmann.   

Abstract

In 2115 women seeking voluntary termination of pregnancy after 49 days of amenorrhea or less, we studied the effect of a single 600-mg dose of mifepristone (RU 486), followed 36 to 48 hours later by the administration of one of two prostaglandin analogues, either gemeprost (1 mg by vaginal suppository) or sulprostone (0.25, 0.375, or 0.5 mg by intramuscular injection). The women were monitored for four hours after prostaglandin administration. Efficacy was indicated by the complete expulsion of the conceptus without the need of an additional procedure. All other results were considered failures, and the pregnancy was then terminated by a surgical method. The overall efficacy rate was 96.0 percent (95 percent confidence interval, 95.0 to 96.8). The failures included persisting pregnancies (1.0 percent), incomplete expulsions (2.1 percent), and the need for hemostatic procedure (0.9 percent). The mean time to expulsion was significantly shorter when sulprostone was given in the high dose (4.5 hours) than when it was given in the two lower doses (13.1 and 19.3 hours) or when gemeprost was given (22.7 hours). The mean duration of uterine bleeding was 8.9 days (range, 1 to 35); one woman received a blood transfusion. Most women had transient abdominal pain after receiving prostaglandin, but there were few other side effects. We conclude that the administration of mifepristone followed by a small dose of a prostaglandin analogue is an effective and safe method for the early termination of pregnancy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2304490     DOI: 10.1056/NEJM199003083221001

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  14 in total

Review 1.  Mifepristone. Separating fact from fiction.

Authors:  R C Henshaw; A A Templeton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

2.  RU 486.

Authors:  A Rosenfield
Journal:  Am J Public Health       Date:  1992-10       Impact factor: 9.308

3.  Medical abortion.

Authors:  P Doherty
Journal:  BMJ       Date:  1992-02-29

4.  Political, economic and ethical aspects of use of medical abortifacients.

Authors:  P J Macrow
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

5.  Acetaminophen as a pain enhancer during voluntary interruption of pregnancy with mifepristone and sulprostone.

Authors:  B Weber; J E Fontan
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  Medical abortion.

Authors:  M Heard; J Guillebaud
Journal:  BMJ       Date:  1992-01-25

7.  In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin.

Authors:  A S Hawes; C S Rock; C V Keogh; S F Lowry; S E Calvano
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

Review 8.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

9.  Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice.

Authors:  C Perronne; Y Cohen; C Truffot-Pernot; J Grosset; J L Vildé; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 10.  Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use.

Authors:  G R Jang; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1997-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.